Cost-Effectiveness, Burden of Disease and Budget Impact of Inclisiran: Dynamic Cohort Modelling of a Real-World Population with Cardiovascular Disease

OBJECTIVE: We aimed to estimate the cost-effectiveness, burden of disease and budget impact of inclisiran added to standard-of-care lipid-lowering therapy in the real-world secondary cardiovascular prevention population in Switzerland. METHODS: An open-cohort Markov model captured event risks by sex...

Descripción completa

Detalles Bibliográficos
Autores principales: Galactionova, Katya, Salari, Paola, Mattli, Renato, Rachamin, Yael, Meier, Rahel, Schwenkglenks, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300545/
https://www.ncbi.nlm.nih.gov/pubmed/35723806
http://dx.doi.org/10.1007/s40273-022-01152-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300545/
https://www.ncbi.nlm.nih.gov/pubmed/35723806
http://dx.doi.org/10.1007/s40273-022-01152-8

Ejemplares similares